Acute haemodynamic response in relation to plasma vardenafil concentrations in patients with pulmonary hypertension

Br J Clin Pharmacol. 2012 Dec;74(6):990-8. doi: 10.1111/j.1365-2125.2012.04303.x.

Abstract

Aims: To evaluate the acute haemodynamic effects of a single oral dose of vardenafil and to study the drug concentration in relation to haemodynamic effects in patients with pulmonary hypertension (PH).

Methods: Sixteen patients with PH (aged 29-85\ years), received one single oral dose of vardenafil (5, 10 or 20 mg). The haemodynamic effect was assessed over a 60 min period. Vardenafil plasma concentrations were measured after 15, 30, 45 and 60 min using liquid chromatography-tandem mass spectrometry.

Results: At 60 min a reduction in mPAP with a median % decrease of -20.3% (range -48.3 to 3.0; P < 0.001) and an increase in cardiac output and the cardiac index with a median % change of 10.6% (range -25.0 to 88.1; P = 0.015) and 12.1% (range -24.0 to 94.4; P = 0.01) respectively was observed. The pulmonary vascular resistance (PVR) was reduced with a median % decrease of -28.9% (range -61.5 to -5.9; P < 0.001), and pulmonary selectivity was reflected by a median percent reduction of -16.9% (range -49.0 to 16.5; P = 0.002; n = 14) in the PVR/systemic vascular resistance ratio. There was a correlation between the plasma concentrations of vardenafil and change in mPAP (r = -0.579, P = 0.019) and between vardenafil concentrations and change in PVR (r = -0.662, P = 0.005).

Conclusions: Vardenafil causes rapid changes in cardiopulmonary haemodynamics and there is a correlation between plasma vardenafil drug concentration and the acute changes in mPAP as well as PVR in patients with PH.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Cardiac Output / drug effects
  • Chromatography, High Pressure Liquid
  • Dose-Response Relationship, Drug
  • Female
  • Hemodynamics / drug effects*
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / metabolism
  • Imidazoles / pharmacokinetics
  • Imidazoles / therapeutic use*
  • Male
  • Middle Aged
  • Piperazines / pharmacokinetics
  • Piperazines / therapeutic use*
  • Pulmonary Circulation / drug effects
  • Statistics as Topic
  • Sulfones / pharmacokinetics
  • Sulfones / therapeutic use
  • Tandem Mass Spectrometry
  • Triazines / pharmacokinetics
  • Triazines / therapeutic use
  • Vardenafil Dihydrochloride
  • Vasodilator Agents / pharmacokinetics
  • Vasodilator Agents / therapeutic use*

Substances

  • Imidazoles
  • Piperazines
  • Sulfones
  • Triazines
  • Vasodilator Agents
  • Vardenafil Dihydrochloride